Correction to: Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers
- 508 Downloads
1 Correction to: Drugs https://doi.org/10.1007/s40265-018-0903-9
Rewording in main text
Section 1, Introduction, paragraph 3, line 1: The following line, which previously read:
“Apatinib [AiTan™ (China); Rivoceranib® (global)] is a”
“Apatinib [Aitan® (brand name in China)], also known as rivoceranib, is a”
The original article has been updated.